PUBLICATIONS:
  • Escudero-Ortiz V, Pérez-Ruixo JJ, Valenzuela B. Development and Validation of a High-Performance Liquid Chromatography Ultraviolet Method for Lapatinib Quantification in Human Plasma. Ther Drug Monit. 2013 In press.
  • Pérez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farré-Alegre J, Pérez-Ruixo JJ. Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. Clin Pharmacokinet. 2013 In press.
  • Navarrete A, Martínez-Alcázar MP, Durán I, Calvo E, Valenzuela B, Barbas C, García A. Simultaneous online SPE-HPLC-MS/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Mar 15;921-922:35-42
  • Pérez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farré-Alegre J, Pérez-Ruixo JJ. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery. Cancer Chemother Pharmacol. 2013 Mar;71(3):693-704.
  • Valenzuela Jiménez B, González Sales M, Escudero Ortiz V, Martínez Navarro E, Pérez Ruixo C, Rebollo Liceaga J, González Manzano R, Pérez Ruixo JJ. Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G. Farm Hosp. 2013;37(2):111-127.
  • Vázquez B, Sureda M, Rebollo J. 'Células dendríticas I: aspectos básicos de su biología y funciones'. Inmunología 2012;31(1):21-30
  • Sureda M, Vázquez B, Rebollo J. 'Células dendríticas II: utilización clínica en vacunación antitumoral'. Inmunología 2012;31(2):43-48
  • Pena FJ, García-Cases FJ, Redal MC, Crespo A, Vegas J, Fernández-Latorre F. 'Estudio prospectivo comparativo de 2 métodos de cálculo individual de la actividad de la actividad de 131-I en el tratamiento del hipertiroidismo: resultados'.
  • Rev Esp Med Nucl Imagen Mol. 2012; 31 (Supl 1): 37
  • Escudero V, Ramón-López A, Duart MJ, Perez-Ruixo JJ, Valenzuela B. 'Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients'. Farm Hosp. Farm Hosp. 2012; 36: 282-291.
  • Ramón-López A, Escudero V, Duart MJ, Pérez-Ruixo JJ, Valenzuela B. 'Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients'. Farm Hosp. 2012; 36:194-206.
  • Ramón-López A, Escudero V, Carbonell V, Pérez-Ruixo JJ, Valenzuela B. 'Population pharmacokinetics of cisplatin applied to personalize the dosage used in cancer patients'. Farm Hosp. 2012; 36: 392-402
  • Rey S. 'Patología de la glándula tiroides'. Autor Libro. Editorial Bubok. Septiembre 2012.
  • Ramón-López A, Escudero V, Duart MJ, Pérez-Ruixo JJ, Valenzuela B. 'Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients'. Farm Hosp. 2012; 36:194-206.
  • Escudero V, Ramón-López A, Duart MJ, Perez-Ruixo JJ, Valenzuela B. 'Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients'. Farm Hosp. Farm Hosp. 2012; 36: 282-291.
  • Ponsati B, Carreño C, Curto-Reyes V, Valenzuela B, Duart MJ, Van den Nest W, Cauli O, Beltran B, Fernandez J, Borsini F, Caprioli A, Di Serio S, Veretchy M, Baamonde A, Menendez L, Barros F, de la Pena P, Borges R, Felipo V, Planells-Cases R, Ferrer-Montiel A. 'An inhibitor of neuronal exocytosis (DD04107) displays long-lasting in vivo activity against chronic inflammatory and neuropathic pain'. J Pharmacol Exp Ther. 2012; 341: 634-645.
  • Pérez-Ruixo C, Valenzuela B, Fernández Teruel C, González-Sales M, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ. 'Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients'. Cancer Chemother Pharmacol. 2012; 69:15-24.
  • Ramón-López A, Escudero V, Carbonell V, Pérez-Ruixo JJ, Valenzuela B. 'Population pharmacokinetics of cisplatin applied to personalize the dosage used in cancer patients'. Farm Hosp. 2012; 36: 392-402.
  • Pérez-Ruixo C, Valenzuela B, Peris JE, Bretcha P, Escudero V, Farré J, Pérez-Ruixo JJ. 'Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery. Cancer Chemotherapy'. Pharmacol. 2012 Dec 30. [Epub ahead of print] González-Sales M, Valenzuela B, Pérez-Ruixo C, Fernández Teruel C, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo JJ. 'Population Pharmacokinetic- Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®)'. Clin Pharmacokinet. 2012; 51: 751-764.
  • Perez-Ruixo JJ, Green B, Doshi S, Wang YM, Mould DR. 'Romiplostim dose response in patients with immune thrombocytopenia'. J Clin Pharmacol. 2012; 52: 1540-1551.
  • Krzyzanski W, Perez Ruixo JJ. 'Lifespan based indirect response models'. J Pharmacokinet Pharmacodyn. 2012; 39: 109-123.
  • Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Pérez-Ruixo JJ. 'Denosumab dose selection for patients with bone metastases from solid tumors'. Clin Cancer Res. 2012; 18: 2648-2657.
  • Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. 'Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours'. Clin Pharmacokinet. 2012; 51: 247-260.
  • Perez Ruixo JJ, Doshi S, Wang YM, Mould DR. 'Romiplostim Dose Response in Patients with Myelodysplastic Syndromes'. Br J Clin Pharmacol. 2012 Nov 21. [Epub ahead of print]
  • Krzyzanski W, Sutjandra L, Perez-Ruixo JJ, Sloey B, Chow AT, Wang YM. 'Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals'. Pharm Res. 2012 Dec 19. [Epub ahead of print]
  • Freeman DJ, McDorman K, Ogbagabriel S, Kozlosky C, Yang BB, Doshi S, Perez-Ruixo JJ, Fanslow W, Starnes C, Radinsky R. 'Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer'. Molecular Cancer 2012 Jul 25; 11:47.
  • Farre J; Duarte M; Sureda M; Bretcha P, Dussan C; Ballester A; Crespo A, Brugarolas A. 'Tratamiento regional del sarcoma y melanoma localmente avanzado de la extremidad mediante la perfusión aislada con tumor necrosis factor α y melfalan asociada a hipertermia'. Cir Esp. 2012;90:114-20. - vol.90 núm 02